Recent Updates
Recently added Catalysts

Liposomal bupivacaine

Phase 3

Surgery | Small molecule | Pain |Pacira BioSciences, Inc.|Last Updated: Apr 23, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedCONTROLLED
Total Trials1
Total Enrollment106
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04117074Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic SurgeryPHASE3 COMPLETED 106Apr 14, 2021Mar 17, 2025Apr 23, 20251 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Analgesia as assessed by pain intensity scores on a visual analog scale
0 to 48 hours postoperatively

Pain intensity will be measured using visual analog scale (VAS) pain intensity scores. The VAS scores pain intensity on a scale of 0-10, where 0 is no pain and 10 is the most severe pain.

Total opioid consumption
0 to 48 hours postoperatively

Total opioid consumption in IV mg morphine equivalents from 0 to 48 hours postoperatively will be compared between the two arms.

Secondary Endpoints
Change in Patient-perceived quality of recovery as assessed by the Quality of Recovery-15 instrument (QoR-15)
Days 1 through 7 post-intervention
Time (days) to return of bowel function (ROBF)
Up to 7 days post-intervention
Number of participants with postoperative ileus
Up to 7 days post-intervention
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Arm 1: Thoracic Epidural Analgesia with bupivicaineEXPERIMENTALThoracic epidural analgesia (TEA): 0.125 % Bupivicaine infusion (5-7 milliliter \[mL\] per hour) intraoperatively with a 3 mL bolus at the end of the operative procedure just prior to emergence from general anesthesia. Postoperatively 0.0625% Bupivicaine until patient-controlled epidural analgesia (PCEA) pump. PCEA pump 0.0625% bupivacaine at 5-7 mL per hour infusion with a 3 mL q20 minutes demand. PCEA discontinuation with oral tolerance.
Arm 2: Surgical Site Infiltration with Liposomal BupivacaineEXPERIMENTALLiposomal bupivacaine (LB) surgical site infiltration: A single 20 mL liposomal bupivacaine vial containing 266 mg of free-base bupivacaine will be mixed with 60 mL of 0.25% bupivacaine hydrochloride (HCl) and then diluted in preservative-free sterile 0.9% saline for maximal volume not to exceed 300 mL. Dilution with 0.9% saline will be dependent upon length of surgical incision per protocol. The solution will be injected using 22-gauge needle in equal distribution into the peritoneum, along the fascia and into the subcutaneous tissues of the surgical wound by trained faculty surgeons.
Interventions
NameTypeDescription
Liposomal bupivacaineDRUGSurgical site infiltration with 20 mL liposomal bupivacaine prior to laparotomy closure.
Thoracic epidural analgesia (bupivacaine)OTHERPerioperative bupivacaine based thoracic epidural placed preoperatively.
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexFEMALE
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Individuals ≥ 18 years of age * Planned laparotomy by the gynecologic oncology service at the sponsor institution. Exclusion Criteria: * Individuals who have a contraindication to thoracic epidural analgesia * Individuals with a coagulation disorder * Individuals with an inf...

Countries:United States
Unlock Eligibility Criteria